

Wiesław Jerzy Cubaś

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/642917/publications.pdf>

Version: 2024-02-01

108
papers

2,318
citations

361045

20
h-index

253896

43
g-index

111
all docs

111
docs citations

111
times ranked

3306
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2018, 175, 225-231.	4.0	441
2	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 77-84.	1.2	327
3	Blood-brain barrier permeability and physical exercise. <i>Journal of Neuroinflammation</i> , 2019, 16, 15.	3.1	148
4	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	1.7	107
5	The Influence of Antidepressants on the Immune System. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 143-151.	1.0	70
6	Seizure following sudden zolpidem withdrawal. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 539-540.	2.5	67
7	Prevalence of self-reported insomnia in general population of Poland. <i>Psychiatria Polska</i> , 2016, 50, 165-173.	0.2	62
8	Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. <i>European Psychiatry</i> , 2006, 21, 516-520.	0.1	47
9	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15.	1.3	38
10	C-reactive protein and cortisol in drug-naïve patients with short-illness-duration first episode major depressive disorder: Possible role of cortisol immunomodulatory action at early stage of the disease. <i>Journal of Affective Disorders</i> , 2014, 152-154, 534-537.	2.0	34
11	The Brain-Skin Axis in Psoriasis: Psychological, Psychiatric, Hormonal, and Dermatological Aspects. <i>International Journal of Molecular Sciences</i> , 2022, 23, 669.	1.8	34
12	The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit – a clinical review. <i>Sleep Medicine</i> , 2020, 69, 127-134.	0.8	32
13	Perspectives for therapy of treatment-resistant depression. <i>British Journal of Pharmacology</i> , 2022, 179, 4181-4200.	2.7	30
14	Prevalence of anxiety disorders in epilepsy. <i>Epilepsy and Behavior</i> , 2018, 79, 1-3.	0.9	29
15	Wilson's disease associated with delusional disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 758-760.	1.0	28
16	Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 444-445.	1.1	27
17	Therapeutic drug monitoring of atypical antipsychotics. <i>Psychiatria Polska</i> , 2017, 51, 1059-1077.	0.2	26
18	Validation of the Hospital Anxiety and Depression Scale in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2016, 58, 97-101.	0.9	24

#	ARTICLE	IF	CITATIONS
19	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 2-7.	1.2	23
20	Ketogenic diet for depression: A potential dietary regimen to maintain euthymia?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110257.	2.5	23
21	Severe skin complications in patients treated with antidepressants: a literature review. <i>Postepy Dermatologii i Alergologii</i> , 2014, 2, 92-97.	0.4	22
22	<p>Ketamine in Bipolar Disorder: A Review</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2707-2717.	1.0	22
23	Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature. <i>Journal of Psychoactive Drugs</i> , 2018, 50, 275-280.	1.0	21
24	Ketogenic diet for schizophrenia: Nutritional approach to antipsychotic treatment. <i>Medical Hypotheses</i> , 2018, 118, 74-77.	0.8	21
25	Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 955-955.	0.8	20
26	Role of copper in depression. Relationship with ketamine treatment. <i>Medical Hypotheses</i> , 2018, 119, 14-17.	0.8	20
27	Psychometric properties and diagnostic utility of the Stateâ€œTrait Anxiety Inventory in epilepsy with and without comorbid anxiety disorder. <i>Epilepsy and Behavior</i> , 2019, 92, 221-225.	0.9	20
28	Peripheral blood lymphocyte subpopulations in patients with bipolar disorder type II. <i>Scientific Reports</i> , 2019, 9, 5869.	1.6	20
29	Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8623.	1.8	20
30	Antidepressants in epilepsy. <i>Neurologia i Neurochirurgia Polska</i> , 2018, 52, 657-661.	0.6	19
31	Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2637-2646.	1.0	19
32	Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 704330.	1.3	19
33	Validation of the Polish version of the Hospital Anxiety and Depression Scale for anxiety disorders in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2018, 84, 162-165.	0.9	18
34	Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. <i>Medicina (Lithuania)</i> , 2020, 56, 67.	0.8	17
35	Expert advice on the management of valproate in women with bipolar disorder at childbearing age. <i>European Neuropsychopharmacology</i> , 2019, 29, 1199-1212.	0.3	16
36	Psychological Functioning of Patients Undergoing Oral Surgery Procedures during the Regime Related with SARS-CoV-2 Pandemic. <i>Journal of Clinical Medicine</i> , 2020, 9, 3344.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Gut Microbiota in Depression: A Focus on Ketamine. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 693362.	1.0	15
38	Antipsychotic drugs in epilepsy. <i>Neurologia I Neurochirurgia Polska</i> , 2019, 53, 408-412.	0.6	15
39	Reevaluating the prevalence and diagnostic subtypes of depressive disorders in epilepsy. <i>Epilepsy and Behavior</i> , 2015, 53, 15-19.	0.9	14
40	Copper and anti-anhedonic effect of ketamine in treatment-resistant depression. <i>Medical Hypotheses</i> , 2020, 144, 110268.	0.8	14
41	Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. <i>Psychiatria Danubina</i> , 2017, 29, 345-348.	0.2	14
42	Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. <i>Psychiatria Danubina</i> , 2019, 31, 585-590.	0.2	14
43	Interictal dysphoric disorder of epilepsy: A continuing diagnostic challenge. <i>Epilepsy and Behavior</i> , 2019, 95, 34-38.	0.9	13
44	Quetiapine abuse and dependence in psychiatric patients: a systematic review of 25 case reports in the literature. <i>Journal of Substance Use</i> , 2014, 19, 388-393.	0.3	12
45	Validation of the Polish version of the Beck Depression Inventory in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2017, 77, 58-61.	0.9	12
46	Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports. <i>Frontiers in Psychiatry</i> , 2019, 10, 520.	1.3	12
47	Efficacy of Ketamine in bipolar depression: focus on anhedonia. <i>Psychiatria Danubina</i> , 2019, 31, 554-560.	0.2	12
48	Low baseline salivary alpha-amylase in drug-naïve patients with short-illness-duration first episode major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 157, 14-17.	2.0	11
49	<p>Clozapine As Transformative Treatment In Bipolar Patients</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2901-2905.	1.0	11
50	Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. <i>Journal of Sleep Research</i> , 2022, 31, e13400.	1.7	11
51	Magnesium, C-reactive protein, and cortisol in drug-naïve patients with short illness-duration, first episode major depressive disorder: possible immunomodulatory role for magnesium. <i>Magnesium Research</i> , 2016, 29, 169-174.	0.4	10
52	<p>Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2539-2551.	1.0	10
53	Ketogenic Diet: A Dietary Modification as an Anxiolytic Approach?. <i>Nutrients</i> , 2020, 12, 3822.	1.7	10
54	Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. <i>Medicine (United States)</i> , 2021, 100, e26769.	0.4	10

#	ARTICLE	IF	CITATIONS
55	A cry for help, do not omit the signs. Dermatitis artefacta â€“ psychiatric problems in dermatological diseases (a review of 5 cases). Medical Science Monitor, 2012, 18, CS85-CS89.	0.5	10
56	A retrospective study of DRESS â€“ drug reaction with eosinophilia and systemic symptoms. Psychiatria Polska, 2017, 51, 1079-1093.	0.2	9
57	<p>Heart rate variability and incidence of depression during the first six months following first myocardial infarction</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1951-1956.	1.0	8
58	Mechanisms of action of the ketogenic diet in depression. Neuroscience and Biobehavioral Reviews, 2019, 107, 422-423.	2.9	8
59	Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review. Cells, 2022, 11, 645.	1.8	8
60	Validation of the Polish Version of the Hamilton Rating Scale for Depression in patients with epilepsy. Epilepsy and Behavior, 2016, 62, 81-84.	0.9	7
61	The neurobiology of addiction. A vulnerability/resilience perspective. European Journal of Psychiatry, 2018, 32, 139-148.	0.7	7
62	Recommendations of the Polish Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. Psychiatria Polska, 2019, 53, 263-276.	0.2	7
63	Dermatitis artefacta--a long way from the first clinical symptoms to diagnosis. Psychiatria Danubina, 2011, 23, 73-5.	0.2	7
64	Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression. Medicina (Lithuania), 2021, 57, 274.	0.8	6
65	Psychogenic axial myoclonus: report on two cases. Neurological Sciences, 2010, 31, 219-222.	0.9	5
66	Sleep Related Amnestic Behaviors due to Zolpidem. Journal of Microbiology and Biotechnology, 2014, 24, 188-194.	0.9	5
67	Psychometric properties of the Polish version of the Hamilton Anxiety Rating Scale in patients with epilepsy with and without comorbid anxiety disorder. Epilepsy and Behavior, 2019, 94, 9-13.	0.9	5
68	Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression. Brain Sciences, 2020, 10, 971.	1.1	5
69	Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review. Frontiers in Psychiatry, 2020, 11, 516.	1.3	5
70	Multiple Comorbidity Profile of Psychiatric Disorders in Epilepsy. Journal of Clinical Medicine, 2021, 10, 4104.	1.0	5
71	Promazine in the treatment of delusional parasitosis. Psychiatria Danubina, 2011, 23, 198-9.	0.2	5
72	Magnesium in drug-naÃ“ve patients with a short-duration, first episode of major depressive disorder: impact on psychopathological features. Magnesium Research, 2013, 26, 192-198.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Ketamine and magnesium common pathway of antidepressant action. <i>Magnesium Research</i> , 2018, 31, 33-38.	0.4	4
74	Screening and diagnosis for mood and anxiety disorders in epilepsy: Polish population reference values. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 351-356.	0.6	4
75	Recommendations of the Polish Psychiatric Association for treatment of affective disorders in women of childbearing age. Part III: Approach to pregnancy loss and unsuccessful in vitro treatment of infertility. <i>Psychiatria Polska</i> , 2019, 53, 277-292.	0.2	4
76	Dysphoria and Irritability – Diagnostic Pitfalls in the Assessment of Interictal Dysphoric Disorder in Epilepsy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4624.	1.0	4
77	Cortisol as an indicator of hypothalamic-pituitary-adrenal axis dysregulation in patients with panic disorder: a literature review. <i>Psychiatria Danubina</i> , 2015, 27 Suppl 1, S445-51.	0.2	4
78	Neurosyphilis presenting with depressive symptomatology: is it unusual?. <i>Acta Neuropsychiatrica</i> , 2008, 20, 110-110.	1.0	3
79	Dependence on zolpidem: Is pharmacokinetics important?. <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 127-127.	1.0	3
80	Low baseline salivary 3-methoxy-4-hydroxyphenylglycol (MHPG) in drug-naïve patients with short-illness-duration first episode major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 161, 4-7.	2.0	3
81	17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S27-S27.	2.3	3
82	Overlapping phenomena of bipolar disorder and epilepsy – a common pharmacological pathway. <i>Psychiatria Danubina</i> , 2015, 27 Suppl 1, S177-81.	0.2	3
83	Refractory schizophrenia treated with clozapine combined with zuclopenthixol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 781-783.	2.5	2
84	What really is a “gold standard” in depression recognition among patients with epilepsy?. <i>Epilepsy and Behavior</i> , 2018, 87, 249.	0.9	2
85	Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110110.	1.2	2
86	No relationship between baseline salivary alpha-amylase and State-Trait Anxiety Inventory Score in drug-naïve patients with short-illness-duration first episode major depressive disorder: An exploratory study. <i>Journal of Clinical and Experimental Dentistry</i> , 2017, 9, 0-0.	0.5	2
87	Commentary concerning treatment of depression in patients with heart failure according to 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2140-2141.	0.8	2
88	Prolactin response to buspirone is not impaired in drug-naïve first episode patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 152-154, 468-473.	2.0	1
89	Diagnosis of psychiatric comorbidities in epilepsy – The role of screening tools. <i>Epilepsy and Behavior</i> , 2019, 101, 106266.	0.9	1
90	Magnesium in Ketamine Administration in Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2021, 14, 430.	1.7	1

#	ARTICLE	IF	CITATIONS
91	The role of eugeroics in the treatment of affective disorders. <i>Psychiatria Polska</i> , 2020, 54, 21-33.	0.2	1
92	Zinc, C-reactive protein, and cortisol in major depressive disorder: an exploratory analysis. <i>Trace Elements and Electrolytes</i> , 2017, 34, 104-106.	0.1	1
93	Neuropsychiatric presentation of Sjögren syndrome. <i>Polish Archives of Internal Medicine</i> , 2019, 130, 68-69.	0.3	1
94	Mood disorders in epilepsy - diagnostic and methodological considerations. <i>Psychiatria Danubina</i> , 2012, 24 Suppl 1, S44-50.	0.2	1
95	Zinc in drug-naïve patients with short-illness-duration first episode major depressive disorder: impact on psychopathological features. <i>Neuroendocrinology Letters</i> , 2014, 35, 741-5.	0.2	1
96	Role of copper and ketamine in major depressive disorder - an update. <i>Psychiatria Danubina</i> , 2019, 31, 520-523.	0.2	1
97	Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases. <i>Frontiers in Psychiatry</i> , 2021, 12, 705190.	1.3	1
98	Cortisol awakening response in drug-naïve panic disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 1581-1585.	1.0	0
99	Impulsivity in drug-naïve panic disorder. <i>European Journal of Psychiatry</i> , 2017, 31, 45-49.	0.7	0
100	Letter to Editor regarding "Characterizing and predicting rates of delirium across general hospital settings". <i>General Hospital Psychiatry</i> , 2018, 53, 80-81.	1.2	0
101	Depression among patients with epilepsy " A diagnostic approach. <i>Epilepsy and Behavior</i> , 2018, 88, 396.	0.9	0
102	Commentary on: Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness, and neurocognitive performance in healthy volunteers. <i>European Neuropsychopharmacology</i> , 2021, 49, 38-39.	0.3	0
103	Factores asociados con la depresión en la enfermedad de Parkinson: un estudio transversal en una población polaca. <i>European Psychiatry (Ed Española)</i> , 2007, 14, 129-134.	0.0	0
104	An overview of interventions in drug-induced weight gain during clozapine treatment. <i>Psychiatria I Psychologia Kliniczna</i> , 2015, 15, 76-80.	0.3	0
105	The use of antiepileptic drugs in the prevention of clozapine-induced seizures. Literature review. <i>Psychiatria I Psychologia Kliniczna</i> , 2015, 15, 71-75.	0.3	0
106	Cardiovascular and metabolic side effects of second-generation antipsychotics - narrative review. <i>European Journal of Translational and Clinical Medicine</i> , 2019, 2, 70-77.	0.0	0
107	Clinical considerations of sleep related amnesic behaviours associated with zolpidem. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2020, 36, 23-31.	0.1	0
108	Salivary 5-hydroxyindole acetic acid (5-HIAA) in drug-naïve patients with short-illness-duration first episode major depressive disorder. <i>Neuroendocrinology Letters</i> , 2014, 35, 746-9.	0.2	0